The Relationship of Diabetes and Smoking Status to Hepatocellular Carcinoma Mortality

Chien-Hsieh Chiang, Chia-Wen Lu, Hsieh-Cheng Han, Shou-Hung Hung, Yi-Hsuan Lee, Kuen-Cheh Yang, Kuo-Chin Huang, Chien-Hsieh Chiang, Chia-Wen Lu, Hsieh-Cheng Han, Shou-Hung Hung, Yi-Hsuan Lee, Kuen-Cheh Yang, Kuo-Chin Huang

Abstract

The relationship of diabetes and smoking status to hepatocellular carcinoma (HCC) mortality is not clear. We aimed to investigate the association of smoking cessation relative to diabetes status with subsequent deaths from HCC.We followed up 51,164 participants (aged 44-94 years) without chronic hepatitis B or C from 1 January 1998 to 31 December 2008 enrolled from nationwide health screening units in a prospective cohort study. The primary outcomes were deaths from HCC.During the study period, there were 253 deaths from HCC. History of diabetes was associated with deaths from HCC for both total participants (adjusted hazard ratio [HR], 2.97; 95% confidence interval [CI], 2.08-4.23) and ever smokers with current or past smoking habits (HR, 1.92; 95% CI, 1.10-3.34). Both never smokers (HR, 0.46; 95% CI, 0.32-0.65) and quitters (HR, 0.62; 95% CI, 0.39-0.97) had a lower adjusted risk of HCC deaths compared with current smokers. Among all ever smokers with current or past smoking habits, as compared with diabetic smokers, only quitters without diabetes had a lower adjusted risk of HCC deaths (HR, 0.37; 95% CI, 0.18-0.78). However, quitters with diabetes were observed to have a similar risk of deaths from HCC when compared with smokers with diabetes. Regarding the interaction between diabetes and smoking status on adjusted HCC-related deaths, with the exception of quitters without history of diabetes, all groups had significantly higher HRs than nondiabetic never smokers. There was also a significant multiplicative interaction between diabetes and smoking status on risk of dying from HCC (P = 0.033). We suggest clinicians should promote diabetes prevention and never smoking to associate with reduced subsequent HCC mortality even in adults without chronic viral hepatitis.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Study flowchart.
FIGURE 2
FIGURE 2
Kaplan–Meier survival curves for never smokers, quitters, and current smokers. The log-rank test is significant with P < 0.0001 between never smokers and quitters, between never smokers and current smokers, and between total participants with different smoking habits. The Log-Rank test is not significant between quitters and current smokers with P = 0.351.

References

    1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118–1127.
    1. Liao SF, Yang HI, Lee MH, et al. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS One 2012; 7:e34779.
    1. Wen CP, Lin J, Yang YC, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 2012; 104:1599–1611.
    1. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135:111–121.
    1. Inoue M, Kurahashi N, Iwasaki M, et al. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control 2009; 20:741–750.
    1. Lai MS, Hsieh MS, Chiu YH, et al. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43:1295–1302.
    1. Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54:533–539.
    1. Brower V. Illuminating the diabetes-cancer link. J Natl Cancer Inst 2012; 104:1048–1050.
    1. Chiang CH, Huang KC. Association between metabolic factors and chronic hepatitis B virus infection. World J Gastroenterol 2014; 20:7213–7216.
    1. Wang P, Kang D, Cao W, et al. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012; 28:109–122.
    1. Chiang CH, Lee LT, Hung SH, et al. Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly. Hepatology 2014; 59:2207–2215.
    1. Chen J, Han Y, Xu C, et al. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies. Eur J C Prev 2015; 24:89–99.
    1. Shau WY, Shao YY, Yeh YC, et al. Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. Oncologist 2012; 17:856–862.
    1. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49:S72–84.
    1. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65–73.
    1. Wang LY, You SL, Lu SN, et al. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control 2003; 14:241–250.
    1. Tseng CH. Type 2 diabetes, smoking, insulin use, and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan. Hepatol Int 2013; 7:693–702.
    1. Ogimoto I, Shibata A, Kurozawa Y, et al. Risk of death due to hepatocellular carcinoma among smokers and ex-smokers. Univariate analysis of JACC study data. Kurume Med J 2004; 51:71–81.
    1. Siegel AB, Conner K, Wang S, et al. Smoking and hepatocellular carcinoma mortality. Exp Ther Med 2012; 3:124–128.
    1. Shih WL, Chang HC, Liaw YF, et al. Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer 2012; 131:2612–2621.
    1. Raffetti E, Portolani N, Molfino S, et al. Role of aetiology, diabetes, tobacco smoking and hypertension in hepatocellular carcinoma survival. Digest Liver Dis 2015; 47:950–956.
    1. Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 2013; 309:1014–1021.
    1. Lu TH, Lee MC, Chou MC. Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics. Int J Epidemiol 2000; 29:336–343.
    1. WHO., Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363:157–163.
    1. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17:2937–2944.
    1. Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60:110–117.
    1. Liu J, Yang HI, Lee MH, et al. Distinct seromarkers predict different milestones of chronic hepatitis B progression. Hepatology 2014; 60:77–86.
    1. Chien YC, Jan CF, Chiang CJ, et al. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees. Hepatology 2014; 60:125–132.
    1. Chiang CH, Lai JS, Sheu JC, et al. The risky body mass index ranges for significant hepatitis B viral load: A campus-based study. Obes Res Clin Pract 2012; 6:e31–e38.
    1. Chiang CH, Yang HI, Jen CL, et al. Association between obesity, hypertriglyceridemia and low hepatitis B viral load. Int J Obes (Lond) 2013; 37:410–415.
    1. Chiang CH, Lai JS, Hung SH, et al. Serum adiponectin levels are associated with hepatitis B viral load in overweight to obese hepatitis B virus carriers. Obesity (Silver Spring) 2013; 21:291–296.
    1. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012; 55:948–958.
    1. Kuo YH, Lu SN, Chen CL, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer 2010; 46:744–751.
    1. Singh S, Singh PP, Roberts LR, et al. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014; 11:45–54.
    1. Kowall B, Rathmann W, Strassburger K, et al. Association of passive and active smoking with incident type 2 diabetes mellitus in the elderly population: the KORA S4/F4 cohort study. Eur J Epidemiol 2010; 25:393–402.
    1. Mozaffarian D, Marfisi R, Levantesi G, et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet 2007; 370:667–675.
    1. Bergman BC, Perreault L, Hunerdosse D, et al. Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes 2012; 61:3156–3166.
    1. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383–393.
    1. Voulgari C, Katsilambros N, Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 2011; 60:1456–1464.
    1. Bensellam M, Laybutt DR, Jonas JC, et al. The molecular mechanisms of pancreatic beta-cell glucotoxicity: recent findings and future research directions. Mol Cell Endocrinol 2012; 364:1–27.
    1. Morimoto A, Ohno Y, Tatsumi Y, et al. Impact of smoking cessation on incidence of diabetes mellitus among overweight or normal-weight Japanese men. Diabetes Res Clin Pract 2012; 96:407–413.
    1. Berry SD, Ngo L, Samelson EJ, et al. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc 2010; 58:783–787.
    1. Chiang CH, Huang KC. Reply. Hepatology 2015; 61:1763–1764.
    1. Chiang CH, Ni YH. Obscure clinical implication of occult hepatitis B virus infection by perinatal transmission despite prophylaxis with hepatitis B vaccination and HBIG Letter. J Hepatol 2012; 57:1401.
    1. Ni YH, Chang MH, Wu JF, et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012; 57:730–735.
    1. Setiawan VW, Wilkens LR, Lu SC, et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015; 148:118–125.quiz e115.
    1. Kurozawa Y, Ogimoto I, Shibata A, et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005; 93:607–610.
    1. Hu G, Tuomilehto J, Pukkala E, et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 2008; 48:129–136.
    1. Sang LX, Chang B, Li XH, et al. Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterol 2013; 13:34.
    1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35:S64–71.
    1. Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108:881–891.quiz 892.
    1. Marchesini G, Forlani G. Diabetes and hepatocellular cancer risk: not only a matter of hyperglycemia. Hepatology 2012; 55:1298–1300.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다